Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€276.25

€276.25

-1.020%
-2.85
-1.020%
€292.81

€292.81

 
20:03 / Tradegate WKN: 867900 / Symbol: AMGN / Name: Amgen / Stock / Biotechnology & Medical Research / Large Cap /
Latest predictions
06.01.26
-2.68%
buy
€305.71
30.12.25
-1.39%
buy
18.12.25
-0.18%
buy
07.12.25
-2.73%
buy
05.12.25
-4.23%
buy
03.12.25
-4.30%
buy
Best running prediction
-
11.05.25
22.57%
buy
Your prediction

Amgen Inc. Stock

A loss of -1.020% shows a downward development for Amgen Inc..
The stock is one of the favorites of our community with 27 Buy predictions and 4 Sell predictions.
With a target price of 292 € there is a slightly positive potential of 5.7% for Amgen Inc. compared to the current price of 276.25 €.
So far the community has only identified positive things for Amgen Inc. stock. The most positive votes were given for criterium "Balance Sheet Risk".

Pros and Cons of Amgen Inc. in the next few years

Pros
?
C******** o* t** e**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Amgen Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Amgen Inc. -1.020% 2.029% 3.084% 9.045% -0.375% 11.841% 43.910%
Incyte Corp. -1.320% 5.022% 12.125% 32.452% 8.264% 22.950% 18.017%
Regeneron Pharmaceuticals Inc. -1.060% 1.137% 4.212% -3.348% -0.754% -0.061% 58.813%
IQVIA Holdings Inc. -0.050% 3.198% 9.057% 4.240% 6.939% 2.051% 32.372%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-14

Die Geldeinnahmen von Amgen (US-Symbol AMGN) deuten auf eine starke Leistung hin, die sich in entscheidenden Finanzmetriken wie Umsatz, Betriebskapital und Rentabilität widerspiegelt. Die Bilanzen des Unternehmens über die Jahre zeigen eine beständige Vermögensbasis und anhaltende Rentabilität. Die Analyse der Cashflow-Berichte zeigt, dass das Unternehmen robuste Betriebscashflows generiert, was auf solide betriebliche Leistung und Liquiditätsmanagement hindeutet.

Gehen wir tiefer in die einzelnen Vorteile und Nachteile der Finanzen von Amgen ein.

Die umfangreichen Vermögenswerte von Amgen, wie in den Jahresbilanzen gezeigt, beinhalten sowohl kurzfristige Vermögenswerte, die eine starke Liquidität signalisieren, als auch längerfristige Vermögenswerte, die eine solide Investition in den Forschungs- und Entwicklungsbereich verdeutlichen.

Comments

Amgen (NASDAQ:AMGN) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating.
Ratings data for AMGN provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -1.39%
Target price 305.712
Change
Ends at 30.12.26

Amgen (NASDAQ:AMGN) had its price target raised by analysts at Argus from $310.00 to $360.00. They now have a "buy" rating on the stock.
Ratings data for AMGN provided by MarketBeat
Show more

Amgen (NASDAQ:AMGN) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating.
Ratings data for AMGN provided by MarketBeat
Show more

News

Can These Dividend Stocks Beat the Market Again in 2026?: https://g.foolcdn.com/editorial/images/849565/pharmacist-talking-to-patient.jpg
Can These Dividend Stocks Beat the Market Again in 2026?

Last year was a rebound one for CVS Health (NYSE: CVS) and Amgen (NASDAQ: AMGN). After underperforming broader equities in 2024, both healthcare giants bounced back in 2025, outperforming the market

2 Dividend Stocks to Double Up on Right Now: https://g.foolcdn.com/editorial/images/846694/nurse-holding-patients-hands.jpg
2 Dividend Stocks to Double Up on Right Now

A volatile trading environment and high inflation should not deter investors from the stock market. These challenges will eventually subside, and equities have performed well over the long term

2 Dividend Stocks to Double Up On Right Now: https://g.foolcdn.com/editorial/images/840837/person-drinking-bottled-drink-with-a-straw.jpg
2 Dividend Stocks to Double Up On Right Now

Earnings season always creates short-term winners and losers. Beverage behemoth Coca-Cola (NYSE: KO) and biotech giant Amgen (NASDAQ: AMGN) were firmly in the former category, as both delivered